HIV/AIDS Archives - Neurology Advisor

Pain

Combination Interventions Needed to Tackle Excess Mortality From Extramedical Opioids

By

Laurel Ranger

May 27, 2020

Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.

Neurocognitive Disorders

Neurocognitive Conditions Among People Living With HIV

By

Linda Peckel

April 23, 2020

Neurologic conditions associated with HIV remain major contributors to morbidity and mortality, and are increasingly recognized in the aging population of individuals living with HIV.

Neurobehavioral Disorders

Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness

By

Zahra Masoud

April 6, 2020

Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.

General Neurology

Telmisartan Adjunct Treatment May Reduce CNS Inflammation During Acute HIV

By

Dibash Das, PhD

March 24, 2020

Telmisartan did not affect biomarkers of central nervous system inflammation or injury when used as an adjunct to ART for acute HIV infection.

General Neurology

Surveillance Estimates Prevalence of Neural Tube Defects in Births to Women With HIV

By

Neurology Advisor Contributing Writer

February 10, 2020

The prevalence of neural tube defects (NTDs) in births to mothers with HIV from 2013 to 2017 was estimated to be 7.0 per 10,000 live births.

Neurodegenerative Diseases

Prevelance of Neural Tube Defect in HIV-Exposed Individuals

January 21, 2020

The prevalence of neural tube defects (NTDs) is 7.0 per 10,000 live births in HIV-exposed pregnancies, which is similar to the prevalence in the general population.

Neuropathy

Prevalence of HIV-Associated Distal Sensory Peripheral Neuropathy in Resource-Limited Settings

By

Sweta Gupta

December 16, 2019

Although the prevalence of distal sensory peripheral neuropathy decreased following initiation of cART in people living with in resource-limiting settings, better strategies are needed.

Pediatric Neurology

Fetal Exposure to Efavirenz May Increase Risk for Microcephaly

December 5, 2019

In utero exposure to efavirenz is associated with an increased risk for microcephaly among children who are HIV-exposed but uninfected.

General Neurology

Updated Labeling for Efavirenz-Containing Products Warns of Possible Late-Onset Neurotoxicity

By

Brian Park, PharmD

October 31, 2019

The Warnings and Precautions section has been updated to address the potential for late-onset neurotoxicity, including ataxia and encephalopathy with efavirenz treatment.

Neurocognitive Disorders

An Overview of HIV-Associated Neurocognitive Disorder

By

Tori Rodriquez, MA, LPC, AHC

October 22, 2019

Rates of HIV-associated dementia have decreased from approximately 50% in the pre-cART era to 2% currently. However, roughly 50% of patients treated with cART have the milder forms of HIV-associated neurocognitive disorder (HAND).